Orchard Therapeutics plc (ORTX)

Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Last trade price
Market Cap 756.82M
Revenue (ttm) 21.84M
Net Income (ttm) -72.92M
Shares Out 45.32M
EPS (ttm) -4.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 372,349
Open 16.65
Previous Close 16.70
Day's Range 16.65 - 16.70
52-Week Range 4.24 - 16.72
Beta 0.55
Analysts Buy
Price Target 21.67 (+29.76%)
Earnings Date Mar 4, 2024

About ORTX

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of conce... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 31, 2018
Employees 166
Stock Exchange NASDAQ
Ticker Symbol ORTX
Full Company Profile

Financial Performance

In 2022, ORTX's revenue was $22.66 million, an increase of 1252.54% compared to the previous year's $1.68 million. Losses were -$150.66 million, 4.20% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ORTX stock is "Buy." The 12-month stock price forecast is $21.67, which is an increase of 29.76% from the latest price.

Price Target
$21.67
(29.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families

24 days ago - GlobeNewsWire

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) One-time treatment with...

25 days ago - GlobeNewsWire

US approves first gene therapy for rare genetic disease

The U.S. Food and Drug Administration said on Monday it had approved UK-based Orchard Therapeutics' gene therapy for the treatment of children with a rare hereditary disease called metachromatic leuko...

25 days ago - Reuters

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient's own hematopoietic stem cells

2 months ago - GlobeNewsWire

Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium

Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases Three oral presentations and seven pos...

2 months ago - GlobeNewsWire

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceut...

2 months ago - GlobeNewsWire

Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases

TOKYO & LONDON & BOSTON--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing novel medicines utiliz...

2 months ago - Business Wire

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

TOKYO and LONDON and BOSTON, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing n...

2 months ago - GlobeNewsWire

Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD

BOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has appro...

4 months ago - GlobeNewsWire

Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Previously reported results from ongoing proof-of-concept study showed extensive metabolic correction, continued cognitive, motor, and physical development, as well as early improvements in skeletal h...

4 months ago - GlobeNewsWire

ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Orchard Therapeu...

4 months ago - Business Wire

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarte...

5 months ago - GlobeNewsWire

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023

New clinical data beyond previously reported neurological and skeletal results demonstrate favorable outcomes for multiple disease manifestations not effectively addressed by the current standard of c...

6 months ago - GlobeNewsWire

Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023

Eight presentations highlight the differentiated profile and broad applicability of the company's HSC gene therapy platform

6 months ago - GlobeNewsWire

Orchard Therapeutics is being bought at a massive premium

Shares of Orchard Therapeutics (NASDAQ: ORTX) almost doubled this morning after Kyowa Kirin Co Ltd (TYO: 4151) announced plans of buying the gene therapy company. Details of Orchard-Kyowa definitive a...

6 months ago - Invezz

ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Orchard Therapeutics plc (NASDAQ: ORTX) to Kyowa Kirin Co., Ltd. is fair to Orchard share...

6 months ago - Business Wire

Orchard Therapeutics shares nearly double on buyout deal

Orchard Therapeutics shares ORTX, -0.61% nearly doubled, to $15.79, after agreeing to be purchased by Japan's Kyowa Kirin 4151, -0.24% for at least $16 per share in cash, plus an additional contingent...

6 months ago - Market Watch

Kyowa Kirin to acquire Orchard Therapeutics for $478 mln

Japanese pharmaceutical firm Kyowa Kirin said on Thursday it would acquire Britain-based biopharmaceutical company Orchard Therapeutics for $477.6 million, aiming to promote the development of new dru...

6 months ago - Reuters

Kyowa Kirin to Acquire Orchard Therapeutics

-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases- -Acquisition enriches Kyowa Kirin's portfolio, enables th...

6 months ago - GlobeNewsWire

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review

PDUFA date set for March 18, 2024 OTL-200 would be the first and only treatment in the U.S. for early-onset MLD Previously published data demonstrated administration of one-time gene therapy enables s...

7 months ago - GlobeNewsWire

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023

Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 12 years of follow-up (median 6.76 years)

8 months ago - GlobeNewsWire

Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA

Reported $6.6M in Q2'23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patient...

9 months ago - GlobeNewsWire

Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel

BOSTON and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, expresses its strong appreciation for the passage of the Newborn Metabolic Scree...

9 months ago - GlobeNewsWire

Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results

BOSTON and LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on...

9 months ago - GlobeNewsWire

Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital

Funding from second closing extends cash runway to mid-2025 to advance the company's HSC gene therapy portfolio through several potential value-creating milestones

10 months ago - GlobeNewsWire